Literature DB >> 28359064

Interleukin 17A and Toll-like Receptor 4 in Patients with Arterial Hypertension.

Tihana Simundic, Bojan Jelakovic, Andrea Dzumhur, Tajana Turk, Ines Sahinovic, Blazenka Dobrosevic, Boris Takac, Jerko Barbic.   

Abstract

BACKGROUND/AIMS: Immune responses are involved in arterial hypertension. An observational cross-sectional case control study was conducted to estimate the association between Toll-like receptor 4 (TLR4) expression and interleukin (IL)-17A serum levels in patients with controlled and non-controlled hypertension.
METHODS: We have enrolled 105 non-complicated otherwise healthy hypertensive patients: 53 with well-controlled blood pressure and 52 non-controlled. TLR4 peripheral monocytes expression and serum IL-17A levels were determined by flow cytometry and ELISA, respectively.
RESULTS: Non-controlled patients exhibited higher TLR4 expression than well-controlled (25.60 vs. 21.99, P=0.011). TLR4 expression was lower in well-controlled patients who were prescribed beta blockers (18.9 vs. 22.6, P=0.005) and IL-17A concentration was higher in patients using diuretics in either group (1.41 vs. 2.01 pg/ml, P<0.001; well-controlled 1.3 vs. 1.8 pg/ml, P= 0.023; non-controlled 1.6 vs. 2.3 pg/ml, P=0.001). Correlation between IL-17A concentration and hypertension duration was observed in non-controlled patients (Spearman correlation coefficient . ρ=0.566, P<0.001) whereas in well-controlled patients a correlation was found between hypertension duration and TLR4 expression (ρ=0.322, P=0.020).
CONCLUSIONS: Arterial hypertension stimulates the immune response regardless of blood pressure regulation status. Prolonged hypertension influences peripheral monocyte TLR4 expression and IL-17A serum levels. Anti-hypertensive drugs have different immunomodulatory effects: diuretics are associated with higher IL-17A concentration and beta-blockers with lower TLR4 expression.
© 2017 The Author(s)Published by S. Karger AG, Basel.

Entities:  

Keywords:  Adaptive immunity; Arterial hypertension; Innate immunity; Interleukin 17A; Toll-like receptor 4

Mesh:

Substances:

Year:  2017        PMID: 28359064     DOI: 10.1159/000471900

Source DB:  PubMed          Journal:  Kidney Blood Press Res        ISSN: 1420-4096            Impact factor:   2.687


  5 in total

1.  Interleukin 17A infusion has no acute or long-term hypertensive action in conscious unrestrained male mice.

Authors:  Sai Sindhu Thangaraj; Camilla Enggaard; Jane Stubbe; Yaseelan Palarasah; Pernille B L Hansen; Per Svenningsen; Boye L Jensen
Journal:  Pflugers Arch       Date:  2022-05-23       Impact factor: 4.458

2.  Sex differences in TLR4 expression in SHR do not contribute to sex differences in blood pressure or the renal T cell profile.

Authors:  Kasey M Belanger; Riyaz Mohamed; R Clinton Webb; Jennifer C Sullivan
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2022-02-02       Impact factor: 3.619

3.  Expression and clinical significance of SATB1 and TLR4 in breast cancer.

Authors:  Xuebo Wang; Xiumei Yu; Qingli Wang; Yingying Lu; Haixia Chen
Journal:  Oncol Lett       Date:  2017-07-12       Impact factor: 2.967

Review 4.  Adaptive Immunity in Hypertension.

Authors:  Tomasz P Mikolajczyk; Tomasz J Guzik
Journal:  Curr Hypertens Rep       Date:  2019-07-18       Impact factor: 5.369

5.  T helper 17 cells in the pathophysiology of acute and chronic kidney disease.

Authors:  David P Basile; Md Mahbub Ullah; Jason A Collet; Purvi Mehrotra
Journal:  Kidney Res Clin Pract       Date:  2021-03-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.